Ubs Group Ag Achilles Therapeutics PLC Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.75 - $1.25 $49,275 - $82,125	65,700 New	65,700 $53,000
Q1 2023 May 12, 2023	BUY	$0.84 - $1.26 $10,398 - $15,597	12,379 New	12,379 $11,000
Q3 2022 Nov 10, 2022	BUY	$2.26 - $3.38 $1,035 - $1,548	458 Added 20.83%	2,657 $6,000
Q2 2022 Aug 10, 2022	SELL	$1.96 - $3.04 $1,383 - $2,146	-706 Reduced 24.3%	2,199 $6,000
Q1 2022 May 16, 2022	SELL	$2.8 - $5.23 $5,924 - $11,066	-2,116 Reduced 42.14%	2,905 $8,000
Q4 2021 Feb 14, 2022	BUY	$4.22 - $8.86 $21,188 - $44,486	5,021 New	5,021 $26,000
Q3 2021 Nov 15, 2021	SELL	$5.81 - $9.93 $2,695 - $4,607	-464 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$9.79 - $17.86 $4,542 - $8,287	464 New	464 $5,000

24.3M

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $47.3M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.